Updating results

6 results for amyloidosis

Sort: Relevance | Date

Inotersen for treating hereditary transthyretin-related amyloidosis [ID1242]

In development [GID-HST10013] Expected publication date: 22 May 2019

Highly specialised technologies guidance In development

Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279]

In development [GID-HST10014] Expected publication date: 21 August 2019

Highly specialised technologies guidance In development

Appeal panel membership

Ashutosh Wechalekar MD, FRCP, FRCPath, DM, NHS representative UK National Amyloidosis Centre, Department of Medicine, University College...

Published March 2019

Block scoping reports

treating hereditary transthyretin-related amyloidosis. Patisiran for treating hereditary transthyretin-related amyloidosis....

Published April 2019

Myeloma: diagnosis and management (NG35)

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

NICE guideline Published February 2016 Last updated October 2018

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014